A Study of the Relationship Between Serum Albumin-Corrected Fructosamine and Type 2 Diabetic Retinopathy.

Publisher: Wiley Country of Publication: United States NLM ID: 101605237 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6753 (Electronic) NLM ISO Abbreviation: J Diabetes Res Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: Nasr City, Cairo : Hindawi Publishing Corporation, [2013]-

Diabetes Mellitus, Type 2*/blood ; Diabetes Mellitus, Type 2*/complications ; Diabetic Retinopathy*/blood ; Diabetic Retinopathy*/epidemiology ; Diabetic Retinopathy*/diagnosis ; Fructosamine*/blood ; Serum Albumin*/metabolism ; Serum Albumin*/analysis; Biomarkers/blood ; Humans ; Male ; Female ; Middle Aged ; Cross-Sectional Studies ; Retrospective Studies ; Aged ; Prevalence ; Adult ; Risk Factors

Objective: To examine the association between albumin-corrected fructosamine (AlbF) levels and the presence of diabetic retinopathy (DR) in adults with Type 2 diabetes mellitus (T2DM).
Methods: This cross-sectional study retrospectively analyzed 1263 inpatients with T2DM. After applying exclusion criteria, 415 patients were included and categorized into DR (n = 174) and non-DR (n = 241) groups based on fundus examination. The association between the AlbF-analyzed both continuously (per 10 μmol/g increment) and categorically (by tertiles)-and DR was assessed using multivariable logistic regression with progressive adjustment for sociodemographic, clinical, and laboratory confounders. Supplementary analyses, including receiver operating characteristic (ROC) curve assessment and interaction testing across predefined subgroups, evaluated the association's robustness and consistency.
Results: The prevalence of DR was 41.9%. Following full adjustment, each 10 μmol/g increment in AlbF was associated with higher odds of having DR (adjusted OR = 1.88, 95% CI: 1.36-2.60; p < 0.001). A significant dose-response relationship was observed (p for trend < 0.001), with patients in the highest AlbF tertile exhibiting 7.20 times the odds of DR (95% CI: 2.82-18.40) compared to the lowest tertile. Furthermore, the association remained consistent across all predefined subgroups (p for interaction > 0.05 for all).
Conclusions: Elevated AlbF was independently associated with the presence of DR in adults with T2DM, demonstrating a significant dose-response relationship. AlbF shows promise as a biomarker candidate for DR identification and stratification. Its potential clinical utility requires validation in larger prospective studies.
(Copyright © 2026 Zejiang Liu et al. Journal of Diabetes Research published by John Wiley & Sons Ltd.)

The authors declare no conflicts of interest.

Diabetes Metab. 2001 Nov;27(5 Pt 1):598-603. (PMID: 11694860)
Prog Retin Eye Res. 2016 Mar;51:156-86. (PMID: 26297071)
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5594-5603. (PMID: 29084332)
Curr Vasc Pharmacol. 2020;18(2):117-124. (PMID: 31057114)
Wien Klin Wochenschr Suppl. 1990;180:69-71; discussion 78-81. (PMID: 2321397)
PLoS One. 2013;8(3):e57762. (PMID: 23469230)
J Gerontol A Biol Sci Med Sci. 2022 Aug 12;77(8):1673-1682. (PMID: 34758092)
Diabetes Care. 2018 Jan;41(Suppl 1):S7-S12. (PMID: 29222372)
Antioxidants (Basel). 2023 Aug 21;12(8):. (PMID: 37627644)
Nutrients. 2022 Jul 25;14(15):. (PMID: 35893904)
Clin Chem. 1987 Dec;33(12):2153-63. (PMID: 3319287)
Lancet Glob Health. 2021 Feb;9(2):e144-e160. (PMID: 33275949)
Cytokine. 2020 Apr;128:154991. (PMID: 32000013)
Diabetologia. 2021 Jul;64(7):1583-1594. (PMID: 33715025)
Clin Biochem. 2017 Feb;50(3):110-115. (PMID: 27777100)
Diabetes Care. 2016 Aug;39(8):1299-306. (PMID: 27457632)
Ophthalmology. 2003 Sep;110(9):1677-82. (PMID: 13129861)
Diabetes Care. 2025 Nov 1;48(11):1942-1950. (PMID: 40997278)
Kidney Int Suppl. 2010 Aug;(117):S41-5. (PMID: 20671744)
Circulation. 2006 Aug 8;114(6):597-605. (PMID: 16894049)
Diabetes Res Clin Pract. 2023 Sep;203:110873. (PMID: 37574136)
Diabetes Res Clin Pract. 2020 Apr;162:108072. (PMID: 32061820)
Mayo Clin Proc. 2021 Feb;96(2):322-331. (PMID: 33549254)
Diabetes Metab J. 2020 Dec;44(6):828-839. (PMID: 33389957)
Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976)
Diabetes Obes Metab. 2022 Sep;24(9):1779-1787. (PMID: 35546274)
Sci Rep. 2019 Aug 19;9(1):12086. (PMID: 31427625)
Diabetes Care. 2013 Jun;36(6):1522-33. (PMID: 23250799)
Diabetes Care. 2025 Feb 01;48(2):164-176. (PMID: 39693267)
Arch Endocrinol Metab. 2023 Mar 10;67(2):262-265. (PMID: 36913679)
Eur J Intern Med. 2023 Mar;109:73-78. (PMID: 36604231)
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3913-8. (PMID: 26087356)
Arch Endocrinol Metab. 2017 May-Jun;61(3):296-304. (PMID: 28699985)
PLoS One. 2022 Jun 16;17(6):e0270019. (PMID: 35709212)
Nephron. 1989;51(3):338-43. (PMID: 2918945)
Curr Diab Rep. 2014;14(11):548. (PMID: 25249070)
J Diabetes Sci Technol. 2015 Mar;9(2):169-76. (PMID: 25591856)
Cureus. 2023 Jan 9;15(1):e33549. (PMID: 36779109)
J Transl Med. 2024 Jul 29;22(1):700. (PMID: 39075573)
Diabetes Technol Ther. 2023 Jun;25(S3):S65-S74. (PMID: 37306444)
Front Immunol. 2025 Jun 16;16:1571576. (PMID: 40589740)

Keywords: Type 2 diabetes; albumin-corrected fructosamine; diabetic retinopathy; fructosamine; serum albumin

4429-04-3 (Fructosamine)
0 (Serum Albumin)
0 (Biomarkers)

Date Created: 20260205 Date Completed: 20260205 Latest Revision: 20260207

20260207

PMC12865125

10.1155/jdr/9275699

41640698